Your Exit PathYourExitPathby Main Street Wealth

HealthcareNAICS 446110

Sell a Independent Pharmacies business

Healthcare services M&A has been the busiest sector by deal count for four straight years. the specialty revenue is highly recurring and durable.

What moves the multiple

Value drivers in independent pharmacies

Healthcare businesses sit within a broad multiple band. These are the specific factors that determine where you land inside it.

Independent Pharmacies-specific

Independent pharmacies with specialty-pharmacy accreditation (URAC, ACHC) or compounding capability trade at meaningful premium — the specialty revenue is highly recurring and durable.

Payer mix (commercial vs government) — commercial-weighted practices command premium

Provider retention post-close (employment agreements + earn-outs standard)

Multiple providers/practitioners (not solo-owner-dependent)

Modern EHR + billing infrastructure

Ancillary revenue lines (imaging, PT, aesthetics, labs)

Independent Pharmacies operations and business context

Diligence risks

What buyers scrutinize

Every category has structural risks that buyers double-click on. Preparing responses in advance keeps them out of the purchase-price adjustment column.

Independent Pharmacies-specific risk

Retail pharmacy margins have been squeezed by PBM reimbursement pressure and DIR fees; buyers apply substantial discounts for high-percentage retail-prescription revenue.

Payer reimbursement rate compression

Physician recruiting difficulty

State-specific corporate practice of medicine (CPOM) restrictions

Stark Law and anti-kickback compliance exposure

Active buyers

Who buys independent pharmacies businesses

Buyer archetype depends on scale. Sub-$1M SDE draws individuals and search funds. $1–3M SDE opens platform and strategic interest. $3M+ EBITDA is full LMM buyer territory.

Physician-services PE platform

PE Platform

Category-specific platforms (Dental Care Alliance, US Dermatology, US Physical Therapy, US Oral Surgery, US Eye) are the primary bidders on $1.5M+ EBITDA practices.

Health system / MSO

Strategic

Regional hospital systems and management services organizations (MSOs) absorb strategic practices at moderate multiples with faster closes.

Physician successor

Individual

Solo/small-group succession to a rising practitioner remains common below the PE threshold ($700K-$1.5M EBITDA).

Playbook

Exit playbook — healthcare

The single largest driver of purchase-price outcome is preparation depth. These are the levers that move the needle in healthcare exits.

  1. 1

    Recruit a second provider before going to market

    18-24 months pre-sale

    Solo-provider practices trade at 30-40% discount to multi-provider peers. Adding a second before sale is often the highest ROI move.

  2. 2

    Move to a modern integrated EHR + billing system

    18-24 months pre-sale

    Legacy systems trigger diligence discounts. Migrations take 6-12 months to stabilize; start early.

  3. 3

    Optimize payer mix and reduce Medicaid concentration

    12-24 months pre-sale

    Commercial-weighted practices command premium multiples. Realistic mix shift takes 12+ months.

  4. 4

    Engage healthcare M&A counsel early — this segment has unique diligence

    6-9 months pre-sale

    CPOM, Stark, anti-kickback, and state-specific licensing overlays require specialist counsel. Standard M&A attorneys under-serve healthcare.

Independent Pharmacies exit planning

FAQ

Independent Pharmacies exits, answered

What is a independent pharmacies business worth?

Owner-operator independent pharmacies businesses trade at 1.8x–3x SDE for typical $500K–$3M SDE ranges. At $3M+ EBITDA scale the same operators sell at 4.5x–7x EBITDA. Multiples in this category are ebitda-based and data-sourced from PitchBook Healthcare Services 2025 + Bass Berry LMM Healthcare Report. Where you land in the range is driven by growth trajectory, revenue mix, customer concentration, and management-team depth beyond the owner.

Who buys independent pharmacies businesses right now?

Active buyer archetypes in healthcare include Physician-services PE platform, Health system / MSO, Physician successor. Which of these bids for your business depends on scale — sub-$1M SDE is typically individual or search-fund territory, $1-3M SDE opens up PE platforms and strategics, and $3M+ EBITDA gets full LMM buyer attention.

What drives multiple expansion in independent pharmacies?

Independent pharmacies with specialty-pharmacy accreditation (URAC, ACHC) or compounding capability trade at meaningful premium — the specialty revenue is highly recurring and durable. Beyond the industry-specific factor, the universal drivers in healthcare are payer mix (commercial vs government) — commercial-weighted practices command premium; provider retention post-close (employment agreements + earn-outs standard); multiple providers/practitioners (not solo-owner-dependent).

What are the biggest risks in selling a independent pharmacies business?

Retail pharmacy margins have been squeezed by PBM reimbursement pressure and DIR fees; buyers apply substantial discounts for high-percentage retail-prescription revenue. Buyers in this category also standardly scrutinize payer reimbursement rate compression and physician recruiting difficulty. Addressing these in advance in a well-prepared CIM materially reduces retrade risk during diligence.

What revenue range makes independent pharmacies sellable to a professional buyer?

Typical transaction range for independent pharmacies is $1.5M–$15M in annual revenue. Below that, buyer pool narrows to individual and small-search-fund. Above that, PE platforms and strategics dominate. NAICS code 446110 — buyers screen by NAICS in most deal sources.

How long does it take to sell a independent pharmacies business?

From the day you engage a broker to close, expect 6–12 months for a well-prepared business in healthcare. The prep work — financial cleanup, addbacks documentation, key-employee retention agreements, real estate lease sorting — is where 3-6 months of the timeline hides. Starting that early is what separates a full-multiple exit from a discounted one.

Data provenance: Valuation multiples anchored in PitchBook Healthcare Services 2025 + Bass Berry LMM Healthcare Report. Buyer names and platforms are cited from public M&A disclosures, SEC filings, and press releases. Nothing on this page is fabricated. Multiples are whole-market ranges — your specific business will price above or below based on the drivers and risks above.

Published March 17, 2025 · Updated August 2, 2026

Ready to explore an exit?

Get matched to a independent pharmacies specialist.

Answer three quick questions. We surface vetted brokers with real independent pharmacies deal experience.

Sukhrobjon (Rob) Ismoilov, M&A Advisor

Schedule a consultation

Rob Ismoilov · M&A Advisor

Main Street Wealth M&A Advisors · 30 min · Free consultation

Accessibility

Display preferences

User preferences that adjust how the site displays. Saved locally on this device.

Text size

Reduce motion

Pause animations and transitions site-wide.

Underline links

Add underlines to every text link so they stand out.

High contrast

Boost contrast between text and backgrounds.

Readable font

Switch to a plain system font with generous spacing.